RT Journal Article
SR Electronic
T1 Barriers and facilitators of Highly Active Antiretroviral Therapy (HAART) adherence among HIV-positive Women in Southern Ethiopia: A Qualitative study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.12.24308289
DO 10.1101/2024.06.12.24308289
A1 Demissie, Alemayehu Abebe
A1 Rensburg, Elsie Janse van
YR 2024
UL http://medrxiv.org/content/early/2024/06/14/2024.06.12.24308289.abstract
AB Background Adherence to Highly Active Antiretroviral Therapy (HAART) medication is the major predictor of HIV/AIDS treatment success. Poor adherence to HAART creates the risk of transmitting HIV, deteriorating health conditions, treatment failure, increased occurrences of drug-resistant HIV, morbidity and mortality. The objective of this study was to explore and describe the experiences of HAART adherence among HIV-positive women in Southern Ethiopia.Methods Semi-structured in-depth interviews (IDIs) were conducted with 12 HIV-positive women in Southern Ethiopia who are adhering and non-adhering to HAART. Interviews were conducted in the local Amharic language and audio recorded with permission from the participants. The interviews were transcribed verbatim, coded for themes, categories and sub-categories and analyzed using a thematic data analysis technic.Results The findings of the study reflected two themes: barriers and facilitators of HAART medication adherence among HIV-positive women. Barriers and facilitators were further categorized into 5 categories. These included patient-related factors, treatment-related factors, psychosocial-related factors, family and community-related factors, and healthcare services-related factors. These categories were further divided into 22 sub-categories. Busy schedule, forgetting the doses, rituals of religion, economic constraints, drug side-effects, pills burden and size, misconceptions about HIV, negative attitudinal disposition towards HAART, refusal to adhere to HAART, depression, lack of hope and courage, stigma and discrimination, relationship with healthcare providers, a working day of HAART clinic, and long waiting time were identified as barriers to HAART adherence. While, family responsibilities, reminder devices, dosage formulation, perceived benefit of HAART, family support, adherence to supporting peer groups, and adherence to counselling/education were identified as facilitators of HAART adherence.Conclusions Adherence to HAART medication is a major challenge among HIV-positive women in Southern Ethiopia. Therefore, tailored strategies to enhance HAART medication adherence should be targeted addressing the barriers identified in the study.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study obtained scientific approval from the scientific committee (Department of Health Studies and ethical clearance (Ref: HSHDC/463/2015) from the College Research Ethics Committee of the University of South Africa (UNISA). Similarly, permission to carry out the study was asked for and gained from the stakeholders, including the Southern Regional Health Bureau and the three public hospitals where the study was conducted. Informed consent was obtained from each participant prior to each interview and every participant was given an opportunity of choosing whether or not she wanted to be interviewed. The researcher considered the essential values of ethical research, which incorporate respect for human autonomy and dignity, justice, beneficence, and non-maleficence. To ensure the reliability and validity of the results, different techniques were applied. These included developing a rapport with participants, creating a coding system, implementing peer review for themes and sub-themes, the triangulation of data sources (including interview transcripts and field notes), and providing a thorough contextualised data description.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.